P0736Skin cancer surveillance uptake in a real-world Australasian Inflammatory Bowel Disease Cohort: Crohn’s Colitis Cure (CCC) data insight’s program

Abstract Background Preventive health remains a vital element of comprehensive inflammatory bowel disease (IBD) care. The increased skin malignancy risk associated with immunosuppressive therapy warrants routine dermatologic screening and is of particular relevance in Australia and New Zealand where incidence rates are among the highest globally1. Real-world data suggest that patient adherence with skin examination are low and inconsistent2. Fragmented coordination, incomplete documentation, competing clinical priorities, and limited patient awareness likely contribute to these gaps. This study examined patterns of proactive dermatologic surveillance among individuals with IBD and identified factors associated with missed preventive care opportunities. Methods A retrospective multisite audit of prospectively documented IBD care was performed. People at increased risk for skin malignancies (history of thiopurine use, or active thiopurines, anti-TNF, or small molecules use were included. De-identified data from the Crohn’s Colitis Care clinical quality registry (15 clinical sites across Australia and New Zealand) were analysed in October 2025 and factors associated with a documented skin check within the previous 12 months were explored. Results Of 6539 people assessed, 4294 (mean age 40.1, 52.3% male) met a clinical indication for skin cancer surveillance. Within this cohort, 2831 (66.2%) had Crohn’s Disease, 1360 (31.7%) ulcerative colitis, and 93 (2.2%) IBD-unclassified. Documented skin check rates demonstrated a socioeconomic gradient (as measured by the Socio-Economic Indexes for Areas), with only 2.2-5.3% of participants in the lower and middle economic deciles (2-7) undergoing screening, compared with 8-12% in the most advantaged deciles (9-10) (p 0.001). Within the same metropolitan location, a marked difference in the rates of documented dermatological checks was seen between private (23.8%) and public services (4.8%) (p 0.001). Other factors independently associated with greater likelihood of a documented skin check included; age (aOR per year increase:1.025, p 0.001), female sex (6.8% vs. 4.6%, OR:1.53, p = 0.029), post-secondary school education (OR:1.68, p = 0.021), and longer disease duration (p = 0.045). People receiving immunomodulators were approximately twice as likely to have received recent screening compared with non-users (p = 0.022). Conclusion Documentation of skin cancer screening among patients with IBD remains suboptimal, suggesting potential gaps in awareness, access, documentation, and consumer education. Facilitating communication between care teams and developing strategies integrated into clinical workflows could better inform and engage consumers and healthcare teams to improve surveillance adherence. References: 1. Roky AH, Islam MM, Ahasan AM, Mostaq MS, Mahmud MZ, Amin MN, Mahmud MA. Overview of skin cancer types and prevalence rates across continents. Cancer pathogenesis and therapy. 2025 Mar 30;3(02):89-100. doi:10.1016/j.cpt.2024.08.002 2. Xu F, Carlson SA, Greenlund KJ. Understanding primary care providers’ attitudes towards preventive screenings to patients with inflammatory bowel disease. Plos one. 2024 Apr 25;19(4):e0299890. doi:10.1371/journal.pone.0299890 Conflict of interest: Dr. Chan, Patrick: No conflicts of interest. Wu, Rodger: No conflicts of interest. Knowles, Simon Robert: No conflicts of interest. Andrews, Jane Mary: Grant:The work I will present was funded via CCCure. CCCure’s funding sources include grants for research and payments for data reports from Pharma including AbbVie, J & J, Takeda, Celltrion, Falk, Ferring, BMS, Janssen, Pfizer, Sandoz Connor, Susan Jane: This project is supported from a grant by The Leona M. and Harry B. Helmsley Charitable Trust. Grant/Research Support: Abbvie, Agency for Clinical Innovation, Amgen, BMS, Chiesi, Celltrion, DrFalk, Ferring, Janssen, Medical Research Future Fund, Pfizer, South Western Sydney Local Health District, Sydney Partnership for Health, Research and Enterprise, Takeda and The Leona M and Harry B Helmsley Charitable Trust Ad Boards: Abbvie, Amgen, BMS, Celltrion, Eli Lilly, Ferring, GSK, Janssen, Organon, Pfizer, Takeda Speaker Fees: Abbvie, Cornerstones Health, Dr Falk, Ferring, Janssen, Pfizer, Sandoz, Sydney IBD School, Takeda Educational Support: DrFalk, Sandoz, Takeda